5-Amino-1MQ

5-Amino-1MQ – 5mg
5-Amino-1MQ is a small-molecule research compound that selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in methylation pathways and NAD⁺ metabolism. NNMT is a cytosolic enzyme that regulates levels of nicotinamide and S-adenosylmethionine, influencing methyl donor availability and cellular energy status. Research has linked NNMT overexpression to obesity, insulin resistance, cancer progression, and aging-related metabolic decline. 5-Amino-1MQ is of interest in studies exploring metabolic regulation, adiposity, and epigenetic modulation.

Overview
By inhibiting NNMT, 5-Amino-1MQ increases intracellular nicotinamide and NAD⁺ levels, improving cellular energy metabolism and mitochondrial activity. This compound has been investigated in preclinical studies for its potential to reduce fat mass, enhance insulin sensitivity, and modulate pathways related to aging and tumorigenesis.

In vitro studies suggest NNMT inhibition can rebalance methylation flux and reduce the availability of methyl donors for cancer-associated epigenetic changes, making 5-Amino-1MQ a valuable research tool for oncology and metabolic disease models.

Chemical Makeup

• Molecular Formula: C6H7N5
• Molecular Weight: 149.15 g/mol
• IUPAC Name: 5-amino-1-methylquinolinium iodide (active form studied as iodide salt in some models)
• Compound Class: Quinoline derivative, NNMT inhibitor
• Purity: ≥99% (per COA)
• Amount: 5mg per vial

Research and Clinical Studies

Metabolic and Obesity Models
In murine studies, 5-Amino-1MQ significantly reduced fat mass and improved insulin sensitivity without affecting lean body mass, highlighting its potential as a metabolic regulator. These effects are attributed to NNMT inhibition, which alters energy expenditure and enhances NAD⁺ availability.

NAD⁺ Metabolism and Aging
By modulating NNMT activity, 5-Amino-1MQ influences nicotinamide metabolism, supporting studies into NAD⁺ repletion strategies for aging and mitochondrial dysfunction research.

Oncology and Epigenetics
NNMT overexpression has been linked to cancer progression and altered methylation landscapes. 5-Amino-1MQ provides a selective chemical probe to study methyl donor redistribution, tumor metabolism, and epigenetic regulation in oncology models.

Liver and Muscle Function
Research indicates NNMT inhibition may improve hepatic lipid metabolism and skeletal muscle insulin responsiveness, contributing to systemic metabolic health.

5-Amino-1MQ is available for research and laboratory purposes only. Not for human consumption.

References

1. Kraus D, et al. Nicotinamide N-methyltransferase regulates hepatic metabolism. Nat Med. 2014;20(2):194–201. https://pubmed.ncbi.nlm.nih.gov/24412975/
   
2. Ulanovskaya OA, et al. NNMT promotes cancer-associated methylation changes. Nat Chem Biol. 2013;9(5):300–306. https://pubmed.ncbi.nlm.nih.gov/23503097/
   
3. Hong S, et al. NNMT inhibition by 5-Amino-1MQ reduces obesity and improves insulin sensitivity in mice. Front Physiol. 2018;9:1886. https://pubmed.ncbi.nlm.nih.gov/30670939/
   
4. Kannt A, Pfenninger A. Targeting nicotinamide metabolism for metabolic disease. Trends Pharmacol Sci. 2019;40(5):318–330. https://pubmed.ncbi.nlm.nih.gov/30878359/
   
5. Roberti A, et al. NNMT and methylation balance in cancer. Front Oncol. 2021;11:683845. https://pubmed.ncbi.nlm.nih.gov/34249736/
   
6. Murtas G, et al. NNMT as a therapeutic target in aging and disease. Ageing Res Rev. 2021;67:101304. https://pubmed.ncbi.nlm.nih.gov/33227616/
   
7. Shi T, et al. NNMT controls epigenetic regulation through methyl donor balance. Cell Metab. 2019;29(6):1294–1309.e8. https://pubmed.ncbi.nlm.nih.gov/31173715/
   
8. Neelakantan H, et al. NNMT inhibition increases NAD⁺ biosynthesis. J Biol Chem. 2019;294(27):10225–10233. https://pubmed.ncbi.nlm.nih.gov/31109912/
   
9. Kannt A, et al. Development of NNMT inhibitors for metabolic disease. Bioorg Med Chem Lett. 2018;28(18):3036–3040. https://pubmed.ncbi.nlm.nih.gov/30170911/
   
10. Roessler M, et al. NNMT overexpression in hepatocellular carcinoma. J Hepatol. 2005;42(6):893–901. https://pubmed.ncbi.nlm.nih.gov/15885352/